Blood test trial to detect pancreatic cancer early
Part of Cancer clinical trials.
This trial studies whether a blood-based test can help detect pancreatic cancer (or strong signs of it) earlier than usual. The goal is to see how well “liquid biopsy” results match real diagnoses and risk levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 40–75 years old.
- You must be able to sign a consent form and follow study blood testing.
- You must not have had recent cancer treatment before the blood draw (details vary by group).
- You must be able to provide enough usable blood samples for the test.
- You must not be pregnant or breastfeeding.
- Recent blood transfusions or certain recent medicines may disqualify you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new blood test to help doctors find cancer earlier. If you are 45 or older and have symptoms that might be cancer, or were recently diagnosed with cancer, you may be able to join.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
This trial uses a blood test (called cfDNA) to look for early signs of pancreatic cancer. It compares results from people with pancreatic cancer, precancerous changes, non-cancerous pancreatic conditions, and healthy individuals to improve early detection.
This study aims to find new ways to detect liver, bile duct, and pancreatic cancers early using a blood test. It may help doctors diagnose these cancers sooner, when they are easier to treat.
This study looks at a special analysis of your blood (called cfDNA fragmentomics) to help find and tell apart certain early pancreatic tumors. If you’re having surgery for one of the listed solid pancreatic tumors, this trial may use your blood samples to improve diagnosis.
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.